Phibro Animal Health Corporation reported significant financial growth in its latest quarterly results, with net sales reaching $373.9 million for the three months ended December 31, 2025, a 21% increase from $309.3 million in the same period last year. For the six months, net sales totaled $737.8 million, marking a 30% rise compared to $569.7 million in the prior year. The company's gross profit also saw a substantial increase, rising to $132.7 million for the quarter, up 30% from $101.9 million, and $252.4 million for the six months, a 36% increase from $185.4 million. This growth was primarily driven by the Animal Health segment, which benefited from the acquisition of a medicated feed additives portfolio from Zoetis, contributing $94.1 million in sales for the quarter.
The company’s operating income surged to $50.3 million for the three months, compared to $25.5 million in the previous year, and $101.6 million for the six months, up from $43.2 million. Net income for the quarter was $27.5 million, a significant increase from $3.2 million, while for the six months, net income reached $54.0 million, compared to $10.2 million in the prior year. The increase in profitability was attributed to higher sales volumes, improved product mix, and increased average selling prices, despite rising input and distribution costs.
Phibro's strategic developments included the completion of the acquisition of Zoetis's medicated feed additives portfolio on October 31, 2024, for approximately $297.5 million. This acquisition has expanded Phibro's product offerings and enhanced its market presence. The company also reported an increase in selling, general, and administrative expenses (SG&A) to $82.3 million for the quarter, up from $76.3 million, largely due to higher employee-related costs and costs associated with its Phibro Forward income growth initiatives.
Operationally, Phibro reported a total of 40.5 million weighted average shares outstanding, with diluted earnings per share of $0.67 for the quarter, compared to $0.08 in the previous year. The company’s cash and cash equivalents stood at $55.5 million as of December 31, 2025, down from $68.0 million at the end of June 2025. The company also noted a working capital increase to $525.9 million, reflecting a strong liquidity position.
Looking ahead, Phibro expressed confidence in its ability to maintain adequate liquidity and meet its operational needs, despite potential macroeconomic challenges and geopolitical tensions, particularly in regions where it operates. The company anticipates continued growth driven by its expanded product portfolio and strategic initiatives aimed at enhancing operational efficiency and market reach.
About PHIBRO ANIMAL HEALTH CORP
Phibro Animal Health Corporation is a global provider of animal health, mineral nutrition, and performance products for livestock, poultry, aquaculture, and companion animals. It develops, manufactures, and markets vaccines, antibacterials, anticoccidials, nutritional supplements, and mineral formulations to farmers, veterinarians, and feed companies worldwide. The company emphasizes innovation, regulatory compliance, and a broad product portfolio to support animal health, productivity, and food safety across diverse markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.